{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059485","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.592488+00:00","generated_at":"2026-06-02T01:11:33.565471+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PepGen Q1 net loss $18.0M, cash $175.2M; key clinical data expected mid-2024","bullets":["Cash and marketable securities $175.2M as of March 31, 2024, funding operations into 2026.","Net loss widened to $18.0M from $16.3M YoY; R&D expense $14.7M, G&A $5.1M.","Preliminary CONNECT1-EDO51 data (5 mg/kg dose) expected mid-2024; FDA orphan/rare pediatric designations granted.","FREEDOM1-DM1 preliminary data from at least 5 mg/kg cohort expected second half 2024.","Raised $86.3M net from February common stock offerings (ATM + underwritten)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059485","json":"https://secwatch.observer/filing/0000950170-24-059485.json","markdown":"https://secwatch.observer/filing/0000950170-24-059485.md","text":"https://secwatch.observer/filing/0000950170-24-059485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024059485/0000950170-24-059485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024059485/pepg-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:11:33.565471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d174627ac075c72feca1d1fe908a0583defaa1d","claim":"PepGen Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, PepGen Inc. announced its financial results for the quarter ended March 31, 2024 and other business updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024059485/0000950170-24-059485-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}